Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 2
2018 1
2019 2
2020 3
2021 1
2022 2
2023 2
2025 6
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.
Bradlow RCJ, Berk M, Kalivas PW, Back SE, Kanaan RA. Bradlow RCJ, et al. CNS Drugs. 2022 May;36(5):451-482. doi: 10.1007/s40263-022-00907-3. Epub 2022 Mar 22. CNS Drugs. 2022. PMID: 35316513 Free PMC article. Review.
N-acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate modulation activity, NAC has been investigated in the treatment of neurodevelopmental disorders …
N-acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of psychiatric disorders. Primarily through its antio …
A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD.
Kanaan RA, Oliver G, Dharan A, Sendi S, Maier A, Mohebbi M, Ng C, Back SE, Kalivas P, Berk M. Kanaan RA, et al. Psychiatry Res. 2023 Sep;327:115398. doi: 10.1016/j.psychres.2023.115398. Epub 2023 Jul 30. Psychiatry Res. 2023. PMID: 37540942 Free article. Clinical Trial.
BACKGROUND: PTSD may involve oxidative stress, and N-acetylcysteine (NAC) may reduce the impact of oxidative stress in the brain. This study aims to investigate the efficacy of adjuvant NAC in people with treatment-resistant PTSD. METHODS …
BACKGROUND: PTSD may involve oxidative stress, and N-acetylcysteine (NAC) may reduce the impact of oxidative …
N-Acetylcysteine for the Treatment of Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder: A Double-Blind, Randomized Controlled Trial.
Back SE, Gray K, Jarnecke AM, Saraiya TC, Santa Ana EJ, Killeen T, Joseph JE, Prisciandaro JJ, Brown DG, Nietert PJ, Stecker T, Rothbaum A, Jones JL, Flanagan JC, Brady KT. Back SE, et al. J Clin Psychiatry. 2025 Aug 27;86(4):25m15803. doi: 10.4088/JCP.25m15803. J Clin Psychiatry. 2025. PMID: 40875537 Clinical Trial.
Objective: Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) are common co-occurring conditions associated with a more severe clinical profile and poorer treatment outcomes than either disorder alone. To date, no medications have proven efficacious …
Objective: Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) are common co-occurring conditions associated w …
A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial to assess the efficacy of adjunctive N-Acetylcysteine for treatment-resistant PTSD: a study protocol.
Maier A, Dharan A, Oliver G, Berk M, Redston S, Back SE, Kalivas P, Ng C, Kanaan RA. Maier A, et al. BMC Psychiatry. 2020 Aug 6;20(1):397. doi: 10.1186/s12888-020-02793-9. BMC Psychiatry. 2020. PMID: 32762663 Free PMC article.
BACKGROUND: Most patients with Posttraumatic Stress Disorder (PTSD) suffer residual symptoms following first-line treatment. Oxidative stress has been implicated in the pathophysiology of PTSD. N-acetylcysteine (NAC) is a precursor of the …
BACKGROUND: Most patients with Posttraumatic Stress Disorder (PTSD) suffer residual symptoms following first-line treatment. O …
The Emerging Role of N-Acetylcysteine in Psychiatry: A Narrative Review of Available Data.
Marazziti D, Caruso V, Cappellato G, Chiarantini I, Gurrieri R, Perrone P, Violi M, Crivelli NSB, Weiss F, Perugi G. Marazziti D, et al. Curr Med Chem. 2025 Sep 23. doi: 10.2174/0109298673365458250901115725. Online ahead of print. Curr Med Chem. 2025. PMID: 40993955
N-acetylcysteine (NAC), a cysteine derivative with a reactive thiol group, possesses antioxidant and anti-inflammatory properties. ...Recent research highlights its potential role in psychiatric disorders through the modulation of oxidative stress and …
N-acetylcysteine (NAC), a cysteine derivative with a reactive thiol group, possesses antioxidant and anti-inflammatory propert …
N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial.
Back SE, Gray K, Santa Ana E, Jones JL, Jarnecke AM, Joseph JE, Prisciandaro J, Killeen T, Brown DG, Taimina L, Compean E, Malcolm R, Flanagan JC, Kalivas PW. Back SE, et al. Contemp Clin Trials. 2020 Apr;91:105961. doi: 10.1016/j.cct.2020.105961. Epub 2020 Feb 19. Contemp Clin Trials. 2020. PMID: 32087337 Free PMC article.
Alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) are two prevalent psychiatric conditions in the U.S. The co-occurrence of AUD and PTSD is also common, and associated with a more severe clinical presentation and worse treatment outcomes acr …
Alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD) are two prevalent psychiatric conditions in the U.S. The c …
Neuropsychiatric Manifestations of COVID-19 Disease and Post COVID Syndrome: The Role of N-acetylcysteine and Acetyl-L-carnitine.
Barlattani T, Celenza G, Cavatassi A, Minutillo F, Socci V, Pinci C, Santini R, Pacitti F. Barlattani T, et al. Curr Neuropharmacol. 2025;23(6):686-704. doi: 10.2174/011570159X343115241030094848. Curr Neuropharmacol. 2025. PMID: 39506442 Free PMC article. Review.
Clinical entities of ongoing symptomatic COVID-19 and Post COVID Syndrome (PCS) mainly present neuropsychiatric symptoms such as dysgeusia, headache, fatigue, anxiety, depression, sleep disturbances, and post-traumatic stress disorder. The pathophysiology of …
Clinical entities of ongoing symptomatic COVID-19 and Post COVID Syndrome (PCS) mainly present neuropsychiatric symptoms such as dysgeusia, …
N-Acetylcysteine treatment during acute stress prevents stress-induced augmentation of addictive drug use and relapse.
Garcia-Keller C, Smiley C, Monforton C, Melton S, Kalivas PW, Gass J. Garcia-Keller C, et al. Addict Biol. 2020 Sep;25(5):e12798. doi: 10.1111/adb.12798. Epub 2019 Jul 7. Addict Biol. 2020. PMID: 31282090 Free PMC article.
Converging epidemiological studies show that a life-threatening event increases the incidence of posttraumatic stress disorder (PTSD), which carries 30% to 50% comorbidity with substance use disorders (SUDs). ...N-Acetylcysteine (NAC) restores d …
Converging epidemiological studies show that a life-threatening event increases the incidence of posttraumatic stress disorder (PT …
N-Acetylcysteine Reverses Anxiety and Oxidative Damage Induced by Unpredictable Chronic Stress in Zebrafish.
Mocelin R, Marcon M, D'ambros S, Mattos J, Sachett A, Siebel AM, Herrmann AP, Piato A. Mocelin R, et al. Mol Neurobiol. 2019 Feb;56(2):1188-1195. doi: 10.1007/s12035-018-1165-y. Epub 2018 Jun 6. Mol Neurobiol. 2019. PMID: 29876880
There is accumulating evidence on the use of N-acetylcysteine (NAC) in the treatment of patients with neuropsychiatric disorders. ...Additional studies are needed to investigate the effects of this agent on glutamatergic modulation and inflammatory markers re …
There is accumulating evidence on the use of N-acetylcysteine (NAC) in the treatment of patients with neuropsychiatric diso …
Effects of N-acetylcysteine treatment on frontal glutamate and GABA levels and associations with drinking quantity in people with co-occurring posttraumatic stress disorder and alcohol use disorder.
Prisciandaro JJ, Jarnecke AM, Joseph JE, Gray KM, Santa Ana EJ, Back SE. Prisciandaro JJ, et al. Psychopharmacology (Berl). 2025 Oct 13. doi: 10.1007/s00213-025-06932-6. Online ahead of print. Psychopharmacology (Berl). 2025. PMID: 41081839
RATIONALE: Though half of people with posttraumatic stress disorder (PTSD) develop alcohol use disorder (AUD), co-occurring PTSD and AUD (PTSD + AUD) is associated with more severe clinical outcomes relative to either alone and little remains known abo …
RATIONALE: Though half of people with posttraumatic stress disorder (PTSD) develop alcohol use disorder (AUD), co-occurring …
19 results